Business

Dr Reddy’s to sell dengue vax in India from 2027

By Sohail Khan 18 September 2026, 9:18 am

Benchmarks
Nifty23,334.7064.11

FEATURED FUNDS★★★★★

Motilal Oswal Midcap Fund Direct-Growth

5Y Return
22 %

Invest Now

Enter search text:

Business News›Industry›Healthcare/Biotech›Pharmaceuticals›QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

Read Today's Paper

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it
Synopsis

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

ICMR maps dengue strains nationwide as India eyes vaccine rollout — Representative Image.

India’s first approved dengue vaccine, QDENGA, is expected to become available in the country’s private market in the first half of 2027, with Dr Reddy’s Laboratories set to promote and distribute the vaccine under a new agreement with Japanese drugmaker Takeda.

The vaccine has been approved for people aged 4 to 60 years.

The Central Drugs Standard Control Organization (CDSCO) approved QDENGA’s marketing authorisation in July 2026. The vaccine is not expected to be available immediately and will enter the private market after the required regulatory processes are completed.

Japan's Takeda bets on dengue vax to reshape India playbook

QDENGA dengue vaccine India: Who can get it and when?

QDENGA has been approved in India for people aged 4 to 60 years.

The vaccine is expected to be available in the first half of 2027, subject to completion of applicable processes with local authorities.

For now, the agreement covers the private market. Takeda said inclusion of QDENGA in India’s public immunisation programme remains a longer-term objective.

The two companies will also work on healthcare-professional engagement and dengue awareness as part of the private-market rollout.

QDENGA vaccine: How many doses and how does it work?

QDENGA, also known as TAK-003, is a live-attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes.

It uses a DENV-2 backbone along with structural proteins from DENV-1, DENV-3 and DENV-4.

The vaccine is given in two doses, three months apart.

Also Read: Karnataka discusses Takeda GCC expansion, innovation partnerships

Takeda said its global clinical programme for QDENGA included more than 60,000 participants across eight dengue-endemic countries.

The company's seven-year Phase 3 TIDES study reported overall efficacy across all four dengue virus serotypes through seven years. These findings relate to the clinical programme conducted by Takeda and are not a guarantee of protection for every vaccinated individual.

Why dengue vaccination is a focus in India

Dengue cases have increased in India over the past two decades, according to data cited by Dr Reddy's.

The company said reported cases have risen 11-fold over 20 years. It also cited a nationwide surveillance study by the Indian Council of Medical Research’s Virus Research and Diagnostic Laboratory, which found all four dengue virus serotypes circulating across multiple parts of India.

According to the study cited by DRL, 1 in 14 patients had infections involving multiple dengue serotypes at the same time.

Dengue cases can occur throughout the year in India, making prevention and early management a continuing public-health concern.

M.V. Ramana, CEO – Global Generics, Dr. Reddy’s Laboratories, said, “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape. Through our collaboration with Takeda, we look forward to making QDENGA available to eligible individuals and contributing to efforts aimed at addressing the country’s dengue burden.”

Dr Mahender Nayak, Head of Intercontinental Markets, International Business Unit, Takeda, said, “Takeda is committed to supporting India’s evolving healthcare needs and expanding access to dengue vaccination. We welcome the recent Parliamentary Committee on Health’s recommendation to consider dengue vaccine for the Universal Immunization Program. This reflects the growing recognition of dengue as a significant public health challenge. In parallel, our private-market collaboration with Dr. Reddy’s will help enable timely private-market access for eligible individuals once QDENGA becomes available in India.”

QDENGA global availability

Takeda said QDENGA has been approved in 43 countries since 2022, including India.

More than 32 million doses have been distributed through public and private programmes in countries including Indonesia, Thailand, Malaysia and Vietnam, as well as parts of Latin America and Europe, according to the company.

The World Health Organization has recommended QDENGA without pre-vaccination screening in high-endemic countries. The vaccine is also included in the WHO List of Prequalified Vaccines, according to Takeda.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

(You can now subscribe to our WhatsApp channel)

Read More News on
QDENGA dengue vaccinedengue vaccine IndiaDr Reddy’s LaboratoriesTakeda Biopharmaceuticalsdengue preventiondengue immunization programdengue virusdengue cases in Indiadengue vaccine approvalWorld Health Organization

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year